Amgen Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent of $6.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent · last filed 2018-04-25
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2018-03-31 was $6.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2017-12-31 was $36.00M, a 80.65% decline year-over-year.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2017-09-30 was -$50.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2017-06-30 was -$201.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2017 was -$288.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2016 was -$15.00M, a 314.29% decline from fiscal 2015.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2015 was $7.00M, a 97.83% decline from fiscal 2014.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2014 was $323.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2018-03-31 | $6.00M 10-Q · filed 2018-04-25 | $42.00M derived: sum of 2 quarters · filed 2018-04-25 | -$8.00M derived: sum of 3 quarters · filed 2018-04-25 | -$209.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$14.00M derived: sum of 2 quarters · filed 2018-02-13 | -$215.00M derived: sum of 3 quarters · filed 2018-02-13 | -$288.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | -$50.00M 10-Q · filed 2017-10-26 | -$251.00M derived: sum of 2 quarters · filed 2017-10-26 | -$324.00M 10-Q · filed 2017-10-26 | -$138.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-06-30 | -$201.00M 10-Q · filed 2017-07-26 | -$274.00M 10-Q · filed 2017-07-26 | -$88.00M derived: sum of 3 quarters · filed 2018-04-25 | -$104.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2017-03-31 | -$73.00M 10-Q · filed 2018-04-25 | $113.00M derived: sum of 2 quarters · filed 2018-04-25 | $97.00M derived: sum of 3 quarters · filed 2018-04-25 | $91.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $186.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $170.00M derived: sum of 2 quarters · filed 2018-02-13 | $164.00M derived: sum of 3 quarters · filed 2018-02-13 | -$15.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | -$16.00M 10-Q · filed 2017-10-26 | -$22.00M derived: sum of 2 quarters · filed 2017-10-26 | -$201.00M 10-Q · filed 2017-10-26 | -$204.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | -$6.00M 10-Q · filed 2017-07-26 | -$185.00M 10-Q · filed 2017-07-26 | -$188.00M derived: sum of 3 quarters · filed 2018-02-13 | -$241.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | -$179.00M 10-Q · filed 2017-04-27 | -$182.00M derived: sum of 2 quarters · filed 2018-02-13 | -$235.00M derived: sum of 3 quarters · filed 2018-02-13 | -$350.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$56.00M derived: sum of 2 quarters · filed 2018-02-13 | -$171.00M derived: sum of 3 quarters · filed 2018-02-13 | $7.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | -$53.00M 10-Q · filed 2016-10-28 | -$168.00M derived: sum of 2 quarters · filed 2016-10-28 | $10.00M 10-Q · filed 2016-10-28 | $128.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | -$115.00M 10-Q · filed 2016-07-29 | $63.00M 10-Q · filed 2016-07-29 | $181.00M derived: sum of 3 quarters · filed 2017-02-14 | $409.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $178.00M 10-Q · filed 2016-05-02 | $296.00M derived: sum of 2 quarters · filed 2017-02-14 | $524.00M derived: sum of 3 quarters · filed 2017-02-14 | $499.00M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $118.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $346.00M derived: sum of 2 quarters · filed 2017-02-14 | $321.00M derived: sum of 3 quarters · filed 2017-02-14 | $323.00M 10-K · filed 2017-02-14 |
| 2014-09-30 | $228.00M 10-Q · filed 2015-11-02 | $203.00M derived: sum of 2 quarters · filed 2015-11-02 | $205.00M 10-Q · filed 2015-11-02 | $194.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | -$25.00M 10-Q · filed 2015-08-05 | -$23.00M 10-Q · filed 2015-08-05 | -$34.00M derived: sum of 3 quarters · filed 2016-10-31 | -$118.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $2.00M 10-Q · filed 2015-04-27 | -$9.00M derived: sum of 2 quarters · filed 2016-10-31 | -$93.00M derived: sum of 3 quarters · filed 2016-10-31 | -$71.00M derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | -$11.00M derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | -$95.00M derived: sum of 2 quarters · filed 2016-10-31 | -$73.00M derived: sum of 3 quarters · filed 2016-10-31 | $2.00M 8-K · filed 2016-10-31 |
| 2013-09-30 | -$84.00M 10-Q · filed 2014-10-29 | -$62.00M derived: sum of 2 quarters · filed 2014-10-29 | $13.00M 10-Q · filed 2014-10-29 | $27.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $22.00M 10-Q · filed 2014-08-05 | $97.00M 10-Q · filed 2014-08-05 | $111.00M derived: sum of 3 quarters · filed 2015-02-19 | -$6.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $75.00M 10-Q · filed 2014-04-30 | $89.00M derived: sum of 2 quarters · filed 2015-02-19 | -$28.00M derived: sum of 3 quarters · filed 2015-02-19 | $62.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | -$103.00M derived: sum of 2 quarters · filed 2015-02-19 | -$13.00M derived: sum of 3 quarters · filed 2015-02-19 | -$78.00M 10-K · filed 2015-02-19 |
| 2012-09-30 | -$117.00M 10-Q · filed 2013-10-29 | -$27.00M derived: sum of 2 quarters · filed 2013-10-29 | -$92.00M 10-Q · filed 2013-10-29 | |
| 2012-06-30 | $90.00M 10-Q · filed 2013-08-06 | $25.00M 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | -$65.00M 10-Q · filed 2013-05-03 | |||
| 2011-12-31 | $40.00M 10-K · filed 2014-02-24 | |||
| 2010-12-31 | $85.00M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |